Patents by Inventor Ganesh Kaundinya

Ganesh Kaundinya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10464996
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 5, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Thomas E. Prod'Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
  • Patent number: 10450361
    Abstract: The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: October 22, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Xiaomei He, Yan Yin, Yin Yin Lin, Brian Collins, Jennifer Murphy, Ganesh Kaundinya
  • Publication number: 20190077857
    Abstract: The present invention relates to the characterization and production of adalimumab.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 14, 2019
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20190079101
    Abstract: Methods of making and evaluating biologic therapeutic products are disclosed.
    Type: Application
    Filed: April 9, 2018
    Publication date: March 14, 2019
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Patent number: 9695244
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: July 4, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20160097074
    Abstract: The invention provides methods, databases and systems for making glycoprotein products having defined properties.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 7, 2016
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Brian Edward Collins, Carlos J. Bosques, Lakshmanan Thiruneelakantapillai, Dorota A. Bulik, Ian C. Parsons, Zachary Shriver, Rajeev Chillakuru, Ganesh Kaundinya
  • Publication number: 20160090409
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Application
    Filed: May 13, 2014
    Publication date: March 31, 2016
    Inventors: Thomas E. PROD'HOMME, Leona E. LING, Carlos J. BOSQUES, Anthony MANNING, Ganesh KAUNDINYA
  • Publication number: 20150368317
    Abstract: The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 24, 2015
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: John ROBBLEE, Xiaomei HE, Yan YIN, Yin Yin LIN, Brian COLLINS, Jennifer MURPHY, Ganesh KAUNDINYA
  • Patent number: 9163047
    Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 20, 2015
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Sucharita Roy, Takashi Kei Kishimoto, Ganesh Kaundinya
  • Publication number: 20150246974
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: September 3, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150204884
    Abstract: Methods of making and evaluating antibody biological therapeutics (biosimilars) for adalimumab, rituximab and panitumumab are disclosed.
    Type: Application
    Filed: May 31, 2013
    Publication date: July 23, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150158943
    Abstract: Production and bioanalytical characterization of determinative parameters of adalimumab is presented.
    Type: Application
    Filed: May 31, 2013
    Publication date: June 11, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150152184
    Abstract: The present invention relates to the characterization and production of panitumumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: June 4, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150147317
    Abstract: The present invention relates to the characterization and production of bevacizumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150141620
    Abstract: The present invention relates to the characterization and production of rituximab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150140608
    Abstract: The present invention relates to the characterization and production of omalizumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150125848
    Abstract: The present invention relates to the characterization and production of alemtuzumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 7, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20150104444
    Abstract: The present invention relates to the characterization and production of trastuzumab. The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) trastuzumab. In some instances, methods herein allow highly resolved evaluation of trastuzumab useful for, inter alia, manufacturing trastuzumab, characterizing trastuzumab, identifying and/or confirming trastuzumab, monitoring the structure of trastuzumab, comparing trastuzumab preparations made over time or made under different conditions, and/or controlling the structure of trastuzumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: April 16, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Publication number: 20140200339
    Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.
    Type: Application
    Filed: November 8, 2013
    Publication date: July 17, 2014
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Sucharita Roy, Takashi K. Kishimoto, Ganesh Kaundinya
  • Patent number: 8715953
    Abstract: The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: May 6, 2014
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ganesh Kaundinya, Zachary Shriver, Mallikarjun Sundaram, Yi-wei Qi, Ram Sasisekharan